Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 42

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 42
---
 liabilities. Regardless of merit or eventual outcome, liability claims may result in:

| ● | decreased                                                                   
 demand for TELI product candidates if such product candidates are approved; |
| ● | injury                                                                      
 to our reputation;                                                          |
| ● | withdrawal                                                                  
 of clinical trial participants;                                             |
| ● | costs                                                                       
 of related litigation;                                                      |
| ● | substantial                                                                 
 monetary awards to patients and others;                                     |
| ● | increased                                                                   
 cost of liability insurance;                                                |
| ● | loss                                                                        
 of revenue; and                                                             |
| ● | the                                                                         
 inability to successfully commercialize our products.                       |

TELI depends upon its key personnel and ability to attract and retain employees.

TELI’s future growth and success depend on its ability to recruit, retain, manage, and motivate employees. The inability to hire or retain experienced management personnel could adversely affect TELI’s ability to execute its business plan and harm its operating results. Due to the specialized scientific and managerial nature of TELI’s business, it relies heavily on its ability to attract and retain qualified scientific, technical, and managerial personnel. The competition for qualified personnel in the pharmaceutical field is intense. Due to this intense competition, TELI may be unable to attract and retain the qualified personnel necessary for the development of its business or to recruit suitable replacement personnel.

| 22 |

TELI is subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing its operations. If TELI fails to comply with these laws, it could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect its business, results of operations and financial condition.

TELI’s operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”), and other anti-corruption laws that apply in countries where it does business. The FCPA and these other laws generally prohibit TELI’s and its employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. TELI is likely to operate in a number of jurisdictions that pose a high risk of potential FCPA violations, and TELI participation in collaborations and relationships with third parties could potentially subject TELI to liability under the FCPA or local